The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of anti-cancer therapeutics
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
MOTNX | 1.52 | N/A | N/A |
MassMutual Fundamental Growth R3 | |||
AIVGX | 15.18 | N/A | N/A |
American Funds International Vntg F-3 | |||
JFAMX | 26.93 | N/A | N/A |
JPMorgan Emerging Markets Equity A | |||
RTDCX | 15.48 | -0.02 | -0.13% |
Russell Inv Multifactor US Equity C | |||
PMVFX | 20.40 | -0.09 | -0.44% |
PGIM Quant Solutions Mid-Cap Val R4 |
A.I.dvisor indicates that over the last year, IMMP has been loosely correlated with XBIT. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if IMMP jumps, then XBIT could also see price increases.
Ticker / NAME | Correlation To IMMP | 1D Price Change % | ||
---|---|---|---|---|
IMMP | 100% | +0.51% | ||
XBIT - IMMP | 34% Loosely correlated | -4.39% | ||
CRVS - IMMP | 32% Poorly correlated | +0.66% | ||
GBIO - IMMP | 31% Poorly correlated | -4.06% | ||
XFOR - IMMP | 31% Poorly correlated | -0.95% | ||
ARCT - IMMP | 31% Poorly correlated | +1.19% | ||
More |
Ticker / NAME | Correlation To IMMP | 1D Price Change % |
---|---|---|
IMMP | 100% | +0.51% |
australia (undefined stocks) | 10% Poorly correlated | +0.03% |
biotechnology (undefined stocks) | 3% Poorly correlated | -0.81% |
cancer (undefined stocks) | 1% Poorly correlated | -1.34% |
drugs (undefined stocks) | 1% Poorly correlated | -0.89% |
therapeutics (undefined stocks) | -1% Poorly correlated | -1.01% |